NBP Insider Trading Activity and SEC Form 4 Filings
NBP insider trading summary
Over the past 12 months, insiders at NovaBridge Biosciences (NBP) reported 6 sales worth $112K by 3 insiders and 1 open-market purchase worth $577K by 1 insider on SEC Form 4. Net insider buying was $466K.
Latest NBP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 18, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Sell | $6K (8,209 @ $0.71) |
| Sep 9, 2026 | Sean Wuxiong Cao | Chief Bus. Development Officer | Sell | $80K (107,978 @ $0.74) |
| Aug 31, 2026 | Cong Claire Xu | EVP, Clinical Development | Sell | $3K (3,282 @ $0.79) |
| Jul 6, 2026 | Cong Claire Xu | SVP, Clinical Development | Sell | $4K (4,485 @ $0.89) |
| Jun 18, 2026 | Phillip Andrew Dennis | Chief Medical Officer | Sell | $6K (8,494 @ $0.66) |
| Jun 1, 2026 | Cong Claire Xu | SVP, Clinical Development | Sell | $14K (3,494 @ $3.94) |
| Apr 24, 2026 | Mark Arnold Hagler | See Remarks | Buy | $577K (230,000 @ $2.51) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.